David Lamond, Director at Quince Therapeutics, Inc. (QNCX), bought 164,104 shares at $1.32 ($216K) on 2023-08-31, disclosed to the SEC on 2023-08-31.
Open-market purchase of $216k QNCX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.31 | 41,026 | $54K | 24.9% |
| 2 | $1.31 | 41,026 | $54K | 24.9% |
| 3 | $1.32 | 41,026 | $54K | 25.1% |
| 4 | $1.32 | 41,026 | $54K | 25.1% |
| Total | $1.31 avg | 164,104 | $216K | 100% |
| Filing → |
| QNCX | BUY | 2023-12-01 | $41K | — | Filing → |
| QNCX | BUY | 2023-08-17 | $620K | — | Filing → |
| AMTI | BUY | 2022-05-23 | $211K | — | Filing → |